Trial Profile
A Safety and Efficacy Study to Evaluate the Potential of Aleglitazar to Reduce Cardiovascular Risk in Coronary Heart Disease (CHD) Patients With a Recent Acute Coronary Syndrome (ACS) Event and Type 2 Diabetes Mellitus (T2D)
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 12 Mar 2024
Price :
$35
*
At a glance
- Drugs Aleglitazar (Primary) ; Clopidogrel
- Indications Acute coronary syndromes; Myocardial infarction; Stroke; Type 2 diabetes mellitus
- Focus Adverse reactions; Registrational; Therapeutic Use
- Acronyms AleCARDIO
- Sponsors Roche
- 01 Feb 2024 Results assessing the impact of age on the prognostic value of NT-proBNP concentration in patients with type-2 diabetes mellitus (T2DM) stabilised after an Acute Coronary Syndrome , published in the Diabetes Research and Clinical Practice
- 02 Apr 2022 This trial has been completed in France, according to European Clinical Trials Database record.
- 06 Apr 2018 Results (n=4303) of post hoc analysis comparing the efficacy and safety of aleglitazar with placebo in patients with established or newly diagnosed type 2 diabetes and recent ACS including unstable angina, non-ST segment elevation myocardial infarction, and ST segment elevation myocardial infarction published in the Journal of Clinical Endocrinology and Metabolism